Welcome
Support Centre
09 February 2010 
ISRCTN Register - International Standard Randomized Controlled Trial Number
Trial registration
Unique identification scheme
International databases
home  |   my details  |   ISRCTN Register  |   mRCT  |   UKCTG  |   links  |   information  |   press
Find trials
ISRCTN Register
tips on searching

Registration
New application
Updating record

Information
introduction
governing board
ISRCTN FAQs
data set
letter of agreement
request information
guidance notes

[ Print-friendly version ]
Early External Cephalic Version (ECV) 2 trial
ISRCTN ISRCTN56498577
ClinicalTrials.gov identifier NCT00141687
Public title Early External Cephalic Version (ECV) 2 trial
Scientific title
Acronym EECV2
Serial number at source MCT-65630
Study hypothesis 1. For women with a foetus in breech presentation, does early External Cephalic Version (ECV) (at 34^0/7 - 35^6/7 weeks) versus delayed ECV (not before 37^0/7 weeks) increase or decrease the likelihood of Caesarean Section (CS)?
2. Is the risk of preterm birth (less than 37^0/7 weeks) lower or higher with early versus delayed ECV?
Ethics approval Ethics approval received from
1. The University of British Columbia Clinical Research Ethics Board on the 18th August 2004 (ref. no.: C04-0348), amendment on 6th October 2004
2. Research Ethics Board of Hamilton Health Sciences Research Ethics Board on the 20th March 2007 (ref: 07-122) (added to the record on 08/11/2007)
Study design Randomised controlled trial
Countries of recruitment International
Disease/condition/study domain Pregnancies with a foetus in breech presentation
Participants - inclusion criteria 1. Women with any breech presentation, aged 18 - 49 years old
2. A live singleton foetus
3. Gestational age of 33^0/7 - 35^6/7 weeks
Participants - exclusion criteria 1. Any contraindication to ECV
2. Previous participation in the EECV2 Trial
3. Any contraindication to early ECV
4. Women who wish a vaginal delivery if the foetus remains breech
5. Any contraindication to labour or vaginal birth
6. Women who wish to deliver by Caesarean Section (CS) if the foetus turns to cephalic
7. Women at increased risk of unstable lie

Please note that the following exclusion criteria was removed from this list on 06/11/2007:
8. Women who plan to move to a non-trial centre prior to delivery
Anticipated start date 01/12/2004
Anticipated end date 31/12/2008
Status of trial Completed
Patient information material EECV2 trial information for Parents and Families available on http://www.utoronto.ca/cmicr/eecv2/pat/index.htm
Target number of participants 1460 women (730 per group) are required. Recruitment complete as of July 2008.
Interventions Women will be randomised to have either an early ECV at 34 - 35 weeks gestation, or a delayed ECV at or after 37 weeks gestation

As of 1st January 2007 the sponsor changed from the Canadian Institutes of Health Research (CIHR) to the current sponsor, the McMaster University Medical Centre (see below).
Primary outcome measure(s) Rate of CS.

Outcomes will be measured at two planned interim analyses:
1. After 500 participants were recruited (analysis complete 02/2007)
2. After 900 participants were recruited (analysis expected to be complete 01/2008)
3. After the full sample of 1460 participants have been recruited
Secondary outcome measure(s) 1. Rate of preterm birth
2. Other outcomes include admission to neonatal intensive care unit more than or equal to 24 hours, perinatal or neonatal mortality or serious neonatal morbidity, serious foetal complications, maternal death or serious maternal morbidity, non-cephalic presentation at birth, women’s views, and health care costs

Outcomes will be measured at two planned interim analyses:
1. After 500 participants were recruited (analysis complete 02/2007)
2. After 900 participants were recruited (analysis expected to be complete 01/2008)
3. After the full sample of 1460 participants have been recruited
Sources of funding Canadian Institutes of Health Research (CIHR) (Canada) - http://www.cihr-irsc.gc.ca (ref: MCT-65630)
Trial website http://www.utoronto.ca/cmicr/eecv2/
Publications
Contact name Dr  Eileen  Hutton
  Address Department of Obstetrics and Gynecology
McMaster University
1200 Main Street West, MDCL 3103
  City/town Hamilton, Ontario
  Zip/Postcode L8N 3Z5
  Country Canada
  Tel +1 905 525 9140 ext. 26654
  Fax +1 905 523 6459
  Email huttone@mcmaster.ca
Sponsor McMaster University Medical Centre (Canada)
  Address c/o Sarah Lampson
Clinical Trial Agreements and Contracts Specialist
1057 Main Street West
Suite 1, Room 103
  City/town Hamilton, Ontario
  Zip/Postcode L8S 1B7
  Country Canada
  Tel +1 905 521 2100
  Fax +1 905 577 8379
  Email lampson@hhsc.ca
Date applied 19/04/2004
Last edited 09/07/2008
Date ISRCTN assigned 22/04/2005
Submit your trial protocol
Submit to Trials journal
Follow us on Twitter
© ISRCTN


BioMed Central